Amgen stock (US0311621009): Biotech leader navigates patent cliffs and pipeline momentum

Amgen Inc., a biotech powerhouse, continues to shape US healthcare with blockbuster drugs like Enbrel and Prolia amid ongoing pipeline investments. Recent developments highlight its focus on obesity and cardiovascular treatments for long-term growth.

Amgen Inc. remains a cornerstone of the US biotechnology sector, known for its portfolio of biologics addressing inflammation, oncology, and bone health. The company reported steady performance in its latest quarterly results, with key products driving revenue despite patent expirations on older drugs. US investors track Amgen closely for its dividend yield and exposure to the $500 billion-plus US biologics market.

The stock traded at $312.45 USD on 05/13/2026 on Nasdaq, according to Yahoo Finance as of 05/13/2026. Shares have shown resilience, up approximately 2.5% over the past month amid broader market volatility in healthcare.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Amgen Inc.
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: US, Europe, Japan
• Key revenue drivers: Enbrel, Prolia, Repatha
• Home exchange/listing venue: Nasdaq (AMGN)
• Trading currency: USD

Amgen: core business model

Amgen pioneered the biotech industry with recombinant DNA technology in the 1980s, launching Epogen as its first product in 1989. Today, it operates as a fully integrated biopharmaceutical company, focusing on human therapeutics derived from biotechnology. The model emphasizes R&D investment, manufacturing scale, and global commercialization, with over 50% of revenue from the US market according to its 2025 10-K filing as of 02/2026.

Amgen's strategy centers on three pillars: rare diseases, oncology/hematology, and general medicine including cardiovascular and inflammation. This diversification mitigates risks from single-product reliance, a lesson learned from past patent cliffs. The company invests about 20% of sales in R&D annually, supporting a pipeline of over 20 molecules in clinical stages.

Main revenue and product drivers for Amgen

Enbrel, approved for rheumatoid arthritis and psoriasis, generated $3.7 billion in worldwide sales for the 12 months ended December 31, 2025, per the company's Q4 2025 earnings release as of 02/04/2026. Prolia and Xgeva, for osteoporosis and bone metastases, contributed $4.2 billion combined, underscoring Amgen's strength in bone health.

Emerging drivers include Repatha for cholesterol reduction, with uptake accelerating due to label expansions, and Tezspire for severe asthma. Oncology products like Kyprolis and Blincyto add high-margin growth. These products collectively represent over 70% of total revenue, providing stability for US investors seeking defensive biotech exposure.

Industry trends and competitive position

The US biotech sector faces biosimilar competition and pricing pressures, yet Amgen holds a top-5 position by market cap. Its scale enables cost-efficient manufacturing, a competitive edge over smaller peers. According to EvaluatePharma World Preview 2026 as of 01/2026, Amgen ranks among leaders in immunology and oncology sales forecasts through 2030.

Competitors like AbbVie and Johnson & Johnson challenge in inflammation, but Amgen's rare disease focus differentiates it. Patent protections on next-gen assets like MariTide (obesity) position it well in high-growth areas.

Why Amgen matters for US investors

Listed on Nasdaq since 1983, Amgen offers US investors direct access to biotech innovation fueling the $4 trillion US healthcare economy. Its products treat prevalent conditions like arthritis affecting 60 million Americans, per CDC data. Dividend payments, raised for 13 consecutive years to $2.25 per share quarterly as of Q1 2026, appeal to income-focused portfolios.

Main revenue and product drivers for Amgen

Amgen's revenue mix reflects its evolution from anemia treatments to a broad portfolio. In Q1 2026, reported April 29, 2026, global product sales reached $7.6 billion, up 8% year-over-year on a reported basis, driven by volume growth in newer launches, according to the Q1 2026 press release as of 04/29/2026.

Conclusion

Amgen Inc. demonstrates enduring strength in biotechnology through a balanced portfolio and robust R&D pipeline. While facing biosimilar headwinds, growth in obesity and cardio assets offers upside potential. US investors value its market leadership, consistent dividends, and role in advancing treatments for chronic diseases prevalent in the American population.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.